鲎抗内毒素因子模拟肽设计合成及生物活性研究
|
摘要
脓毒症(sepsis)和脓毒性休克是导致危重病患者死亡的主要原因之一,据统计,全球每年因脓毒症死亡的病人高达100 万以上,病死率高达40-60%。内毒素(Lipopolysaccharide,LPS)是引起脓毒症的主要启动子。LPS 通过血浆LPS 结合蛋白(LBP)转运,与单核/巨噬细胞膜上的受体CD14 结合,形成LPS-CD14复合物后再与跨膜受体TLRs 结合,将外源信号转入胞内,导致单核/巨噬细胞活化,释放TNF-α、IL-6 等细胞因子,介导脓毒症的发生。在脓毒症患者中,LPS 的检出率、检出水平均与病情及预后密切相关。因此,封闭LPS 的活性是从源头上防治内毒素血症的关键。
国内外针对内毒素血症的防治策略目前主要有抑制LPS 的合成、阻断LPS 与其受体的结合、阻断LPS 的胞内信号转导、抗细胞因子疗法、糖皮质激素治疗等措施,但均收效甚微。多粘菌素B(PMB)虽能有效中和LPS,但其严重的毒副作用又限制了其临床应用。其他抗菌抗LPS 蛋白,如杀菌性/通透性增加蛋白、鲎抗内毒素因子及其衍化多肽和一些天然抗菌抗内毒素肽的研究大多处于实验阶段,至今仍无有效低毒的药物应用于临床,因此研制高亲和力、能中和细菌LPS,同时兼有杀菌活性的药物是当今世界医学领域研究的重点。
如何能从源头上封闭LPS 的生物活性、阻止和切断其所致一系列炎症性“瀑布”反应呢?据文献报道,美洲鲎和东方鲎的鲎抗内毒素因子(LALF 及TALF)在体外和动物体内具有显著的抗G-杆菌及中和LPS 活性。LALF 高亲和性地以剂量依赖方式结合LPS 并封闭其生物学活性,对脓毒症小鼠模型具有显著保护作用,能有效延长其生命,降低死亡率,抑制LPS 诱导的TNFα分泌,避免脏器损伤。进一步采用LALF 的抗菌抗LPS 活性功能区即第31-52 氨基酸残基序列的研究发现,不论是预防性或是治疗性给予LALF31-52,均可显著保护暴发性腹膜脓毒症模型小鼠,改善全身性的TNFα反应,减少器官损害,增加生存率。迄今的研究还证实,TALF 41-53 是结合LPS 的最小序列,TALF29-59具有与LPS 结合最大潜能。
前人的研究成果为我们进一步的研究奠定了坚实基础,为了能便捷获得大量有效
Sepsis and septic shock is the most frequent cause of death in critical ill patients with a high mortality about 40-60%. Lipopolysaccharide(LPS) usually called endotoxin, is the main initiator of sepsis. By binding with lipopolysaccharide-binding protein(LBP), a LPS-CD14 compound is formed, which together with the Toll-like receptors on the cytoplasmic membrane of mononuclear/ macrophage, thus activates the signal transduction pathway, induces cytokines such as TNF-α, IL-6 etc release, which at last results in sepsis, septic shock or even death. In patients with severe sepsis, the endotoxin level had strong correlation with prognosis, therefore neutralizing LPS would be the key step in the treatment of sepsis.
The promising strategies targeting sepsis are preventing LPS from binding to its receptors, blockage of LPS intracellular signal transduction, antagonism of cytokine and application of glucocorticoids,but unfortunately all these therapies got little clinical benefits. Although polymyxin B has the effectiveness of neutralizing LPS, but the toxical and side effects forbid its wide clinical utilization. Other anti-LPS proteins such as Bactericidal/permeability increasing protein(BPI), Limulus Anti-lipopolysaccharide factor(LALF) and other peptides derived from them as well as other natural antibacterial/LPS peptides are still under experimental trials. There is no effective and safe drugs available till now. The ideal drugs with high affinity to LPS along with bactericidal activity is at the front line in contemporary medical study.
How to block the LPS bioactivity at the very beginning thus to prevent the inflammatory cascade reaction from the LPS activation? The LALF and TALF from both limulus polyphemus and Tachypleus tridentatus Leach have been proved striking anti-gram negative bacillus as well as anti-LPS effects in vitro and in vivo. The LALF can bind to LPS with high affinity in a dose dependent manner and thereafter block the bioactivity of LPS. LALF demonstrated conspicuous protective effect in the sepsis mice model manifested by prolonged life span and decreased mortality. Hoess’s work verify that
the 31st to 52nd amino-acid residue (LALF 31-52) is the functional domain of LALF. In a model in mice with peritoneal fulminating sepsis, LALF31-52 showed both preventive and therapeutical effects which can obviously increase the survival rate of mice under LPS attack. Above studies also show that LALF31-52 is the minimum sequence .The another study proves that TALF 41-53 is also the minimum sequence and the TALF29-59 has the maximum binding potential to LPS. Previous work has laid a solid foundation for further study but unfortunately, taking advantage of nature resources have been confined by the fact that Tachypleus tridentatus Leach being on the verge of extinction. In order to circumvent this dilemma, based on the analysis of LALF and TALF structural features as well as their functional domains by way of bioinformatics methods, we designed a series of MPLALFS ( modeling peptides from Limulus anti-lipopolysaccharide factor ) by computational molecular modeling and then subjected them to chemosynthesis as well as in vitro and in vivo bioactivity studies. Two MPLALFS, the RREMP and TYS1 with optimal anti-LPS and anti-bacterial effects were obtained. Results: 1. The molecular structure, physico-chemical property and molecular dynamic parameters of LALF and TALF and their functional domains were obtained by analyzing with online PHD and GOR in combination with Antheprot 5.0 and APD, which gave abundant information for molecular modeling .Our experience indicated that PHD method was superior to GOR method. 2. The sequences of MPLALFS were successfully got by computational simulation with appropriate allostery and modification. 3. Sixteen MPLALFS were successfully synthesized by the automatic and manual combinated approach . 4. The anti-LPS efficiency of these modeling peptides were screened and tested by limulus Amebocyte Lysate test, biosense, cytokine stimulating test, MTT test, anti-bacterial test, LPS-neutralizing test and protecting test in vitro or vivo. There were three peptides, the S4, RREMP and TYS1 with ideal anti-LPS and anti-bacterial effects were obtained from 16 MPLALFS. 5. RREMP and TYS1 could effectively inhibit the TNF-αrelease induced by LPS and had a potent action against lethal dose LPS attack in mice. Both peptides at the
minimum concentration of 5μM could make a averagely 60% of mice survive in seven days after LPS attack. The survival time was increased obviously. 6. Both RREMP and TYS1 showed a potent and stable anti-LPS effects both in vitro and in vivo in comparison with that of peptides reported in literatures would make them become very promising pro-drugs. 7. After changing the salt from trifluoroacetic acid to acetate in the synthesis process, S4 and S1 showed a dramatic changes in their bioactivities. S4 lost its good anti-LPS property in vitro but S1 got a wider anti-bacterial spectrum and more powerful anti-bacterial ability. This suggested that special salts could change the peptides’bioactivity. Conclusions 1. Without maxicomputer and expensive commercial software, we had successfully completed the molecular design of 15 sequences of MPLALFs by using economic, practical and timely minicomputer with common software and net servers. Of which there were 2 MPLALFs with ideal anti-LPS and anti-bacterial effects had been obtained. The methods we adopted in the study saved us a lot of time and experiment funds. 2. That the change of salt treatment in the peptide synthesis could radically affect the bioactivity of peptide is so far the first report, which suggested that the salt change may be a key factor to the maintenance of peptides’bioactivity. 3. RREMP and TYS1 had ideal and stable anti-LPS effects both in vitro and in vivo. Both peptides could effectively inhibit the TNF-αrelease induced by LPS and showed not only a powerful efficiency against LPS lethal dose attack in mice but also the bioactivity against G-and G+ bacteria in vitro. Otherwise, another peptide S4 also had a stronger anti-LPS effect in vitro. These three peptides are all the new molecules designed by ourselves and have the full intellectual property rights. The patent protection of them has been requesting. 4. As for the second structure analyzing method of protein or peptide, the PHD based on the neural network algorithm was superior to GOR based on the information theory algorithm. In the molecular design of modeling peptide, the minimum domain conservation and precise sequence arrangement of a protein or a peptide, as well as molecular cyclization may be the key to the ideal bioactivity.
国内外针对内毒素血症的防治策略目前主要有抑制LPS 的合成、阻断LPS 与其受体的结合、阻断LPS 的胞内信号转导、抗细胞因子疗法、糖皮质激素治疗等措施,但均收效甚微。多粘菌素B(PMB)虽能有效中和LPS,但其严重的毒副作用又限制了其临床应用。其他抗菌抗LPS 蛋白,如杀菌性/通透性增加蛋白、鲎抗内毒素因子及其衍化多肽和一些天然抗菌抗内毒素肽的研究大多处于实验阶段,至今仍无有效低毒的药物应用于临床,因此研制高亲和力、能中和细菌LPS,同时兼有杀菌活性的药物是当今世界医学领域研究的重点。
如何能从源头上封闭LPS 的生物活性、阻止和切断其所致一系列炎症性“瀑布”反应呢?据文献报道,美洲鲎和东方鲎的鲎抗内毒素因子(LALF 及TALF)在体外和动物体内具有显著的抗G-杆菌及中和LPS 活性。LALF 高亲和性地以剂量依赖方式结合LPS 并封闭其生物学活性,对脓毒症小鼠模型具有显著保护作用,能有效延长其生命,降低死亡率,抑制LPS 诱导的TNFα分泌,避免脏器损伤。进一步采用LALF 的抗菌抗LPS 活性功能区即第31-52 氨基酸残基序列的研究发现,不论是预防性或是治疗性给予LALF31-52,均可显著保护暴发性腹膜脓毒症模型小鼠,改善全身性的TNFα反应,减少器官损害,增加生存率。迄今的研究还证实,TALF 41-53 是结合LPS 的最小序列,TALF29-59具有与LPS 结合最大潜能。
前人的研究成果为我们进一步的研究奠定了坚实基础,为了能便捷获得大量有效
Sepsis and septic shock is the most frequent cause of death in critical ill patients with a high mortality about 40-60%. Lipopolysaccharide(LPS) usually called endotoxin, is the main initiator of sepsis. By binding with lipopolysaccharide-binding protein(LBP), a LPS-CD14 compound is formed, which together with the Toll-like receptors on the cytoplasmic membrane of mononuclear/ macrophage, thus activates the signal transduction pathway, induces cytokines such as TNF-α, IL-6 etc release, which at last results in sepsis, septic shock or even death. In patients with severe sepsis, the endotoxin level had strong correlation with prognosis, therefore neutralizing LPS would be the key step in the treatment of sepsis.
The promising strategies targeting sepsis are preventing LPS from binding to its receptors, blockage of LPS intracellular signal transduction, antagonism of cytokine and application of glucocorticoids,but unfortunately all these therapies got little clinical benefits. Although polymyxin B has the effectiveness of neutralizing LPS, but the toxical and side effects forbid its wide clinical utilization. Other anti-LPS proteins such as Bactericidal/permeability increasing protein(BPI), Limulus Anti-lipopolysaccharide factor(LALF) and other peptides derived from them as well as other natural antibacterial/LPS peptides are still under experimental trials. There is no effective and safe drugs available till now. The ideal drugs with high affinity to LPS along with bactericidal activity is at the front line in contemporary medical study.
How to block the LPS bioactivity at the very beginning thus to prevent the inflammatory cascade reaction from the LPS activation? The LALF and TALF from both limulus polyphemus and Tachypleus tridentatus Leach have been proved striking anti-gram negative bacillus as well as anti-LPS effects in vitro and in vivo. The LALF can bind to LPS with high affinity in a dose dependent manner and thereafter block the bioactivity of LPS. LALF demonstrated conspicuous protective effect in the sepsis mice model manifested by prolonged life span and decreased mortality. Hoess’s work verify that
the 31st to 52nd amino-acid residue (LALF 31-52) is the functional domain of LALF. In a model in mice with peritoneal fulminating sepsis, LALF31-52 showed both preventive and therapeutical effects which can obviously increase the survival rate of mice under LPS attack. Above studies also show that LALF31-52 is the minimum sequence .The another study proves that TALF 41-53 is also the minimum sequence and the TALF29-59 has the maximum binding potential to LPS. Previous work has laid a solid foundation for further study but unfortunately, taking advantage of nature resources have been confined by the fact that Tachypleus tridentatus Leach being on the verge of extinction. In order to circumvent this dilemma, based on the analysis of LALF and TALF structural features as well as their functional domains by way of bioinformatics methods, we designed a series of MPLALFS ( modeling peptides from Limulus anti-lipopolysaccharide factor ) by computational molecular modeling and then subjected them to chemosynthesis as well as in vitro and in vivo bioactivity studies. Two MPLALFS, the RREMP and TYS1 with optimal anti-LPS and anti-bacterial effects were obtained. Results: 1. The molecular structure, physico-chemical property and molecular dynamic parameters of LALF and TALF and their functional domains were obtained by analyzing with online PHD and GOR in combination with Antheprot 5.0 and APD, which gave abundant information for molecular modeling .Our experience indicated that PHD method was superior to GOR method. 2. The sequences of MPLALFS were successfully got by computational simulation with appropriate allostery and modification. 3. Sixteen MPLALFS were successfully synthesized by the automatic and manual combinated approach . 4. The anti-LPS efficiency of these modeling peptides were screened and tested by limulus Amebocyte Lysate test, biosense, cytokine stimulating test, MTT test, anti-bacterial test, LPS-neutralizing test and protecting test in vitro or vivo. There were three peptides, the S4, RREMP and TYS1 with ideal anti-LPS and anti-bacterial effects were obtained from 16 MPLALFS. 5. RREMP and TYS1 could effectively inhibit the TNF-αrelease induced by LPS and had a potent action against lethal dose LPS attack in mice. Both peptides at the
minimum concentration of 5μM could make a averagely 60% of mice survive in seven days after LPS attack. The survival time was increased obviously. 6. Both RREMP and TYS1 showed a potent and stable anti-LPS effects both in vitro and in vivo in comparison with that of peptides reported in literatures would make them become very promising pro-drugs. 7. After changing the salt from trifluoroacetic acid to acetate in the synthesis process, S4 and S1 showed a dramatic changes in their bioactivities. S4 lost its good anti-LPS property in vitro but S1 got a wider anti-bacterial spectrum and more powerful anti-bacterial ability. This suggested that special salts could change the peptides’bioactivity. Conclusions 1. Without maxicomputer and expensive commercial software, we had successfully completed the molecular design of 15 sequences of MPLALFs by using economic, practical and timely minicomputer with common software and net servers. Of which there were 2 MPLALFs with ideal anti-LPS and anti-bacterial effects had been obtained. The methods we adopted in the study saved us a lot of time and experiment funds. 2. That the change of salt treatment in the peptide synthesis could radically affect the bioactivity of peptide is so far the first report, which suggested that the salt change may be a key factor to the maintenance of peptides’bioactivity. 3. RREMP and TYS1 had ideal and stable anti-LPS effects both in vitro and in vivo. Both peptides could effectively inhibit the TNF-αrelease induced by LPS and showed not only a powerful efficiency against LPS lethal dose attack in mice but also the bioactivity against G-and G+ bacteria in vitro. Otherwise, another peptide S4 also had a stronger anti-LPS effect in vitro. These three peptides are all the new molecules designed by ourselves and have the full intellectual property rights. The patent protection of them has been requesting. 4. As for the second structure analyzing method of protein or peptide, the PHD based on the neural network algorithm was superior to GOR based on the information theory algorithm. In the molecular design of modeling peptide, the minimum domain conservation and precise sequence arrangement of a protein or a peptide, as well as molecular cyclization may be the key to the ideal bioactivity.
引文
1. Tadros T, Traber DL,Heggers JP,et al .Effects of interleukin-1alpha administration on intestinal ischemia and reperfusion injury, mucosal permeability, and bacterial translocation in burn and sepsis. Ann-Surg. 2003; 237(1):101-109.
2. Darveau RP. Lipid A diversity and the innate host response to bacterial. Curr. Opin. Microbiol. 1998, 1: 36-42
3. Verhoef J, Hustinx WM, Frasa H, et al. Issues in the adjunct therapy of severe sepsis. J. Antimicrob. Chemother. 1996, 38(20): 167
4. Angus DC,Linde-Zwirble WT,Lidicker J, et al.Epidemiology of severe sepsis in the United States:analysis Of incidence,outcome,and associated costs of care. Crit. Care Med. 2001, 29(7): 1303-1310
5. rawford JH, Yang S, Zhou M,et al. Down-regulation of hepatic CYP1A2 plays an important role in inflammatory responses in sepsis. Crit Care Med. 2004;32(2):502-508
6. Hoshino K,Takeuchi O,Kawai T.et al.Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol. 1999; 162(7): 3749-3752
7. Waage A, Brandtzaeg P, Halstensen A, et al.. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome J. Exp. Med. 1989 169: 333-338
8. Vincent JL, Sun Q, Dubois MJ. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clini Infec Disea. 2002;34:1084-1093.
9. Ma J, Chen T, Mandelin J, et al. Regulation of macrophage activation. Cell Mol Life Sci. 2003;60(11):2334-2346.
10. Ried C, Wahl C, Miethke T, etal. High Affinity Endotoxin-binding and Neutralizing Peptides Based on the Crystal Structure of Recombinant Limulus Anti-lipopolysaccharide Factor. J. Biol. Chem, 1996 ,271(8):28120-28127
11. Kloczewiak M, Black KM, Loiselle P,et al.Synthetic peptides that mimic the binding site of hor seshoe crab antilipopolysaccharide factor.J Infect Dis,1994,170(6):1490-7
12. Roth RI, Su D, Child AH,et al.Limulus antilipopolysaccharide factor prevents mortality late in the course of endotoxemia. J Infect Dis, 1998 ,177(2):388-94
13. Warren HS, Glennon ML, Wainwright N, et al.Binding and neutralization of endotoxin by Limulus antilipopolysaccharide factor. Infect Immun ,1992 ,60(6):2506-13
14. Hoess A, Watson S, Siber G.R, et al.Crystal structure of an endotoxin-neutralizing protein from the horseshoe crab,Limulus anti-LPS factor, at 1.5? resolution. J EMBO,1993,12(9):3351-3356
15. Alpert G, Baldwin G, et al.Thompson C, Limulus antilipopolysaccharide factor protects rabbits from meningococcal endotoxin shock. J Infect Dis ,1992 ,165(3):494-500
16. Dong-Ning Wang, Jie-Wu Liu, Guan-Zhen Yang,et al.Cloning of Anti-LPS Factor cDNA from Tachypleus tridentatus,Expression in Bombyx mor/Larvae and Its Biological Activity In Vitro.Molecular biotechnology.2002,21:1-7
17. Maribel G. V, Luis A. G, Osvaldo R, et al. A Limulus Antilipopolysaccharide Factor-Derived Peptide Exhibits a New Immunological Activity with Potential Applicability in Infectious Diseases[J]. Clinical and Diagnostic Laboratory Immunology, 2000, 7(4):669-675.
18. Maribel G. V, J.C. Alvarez-Obregon, I. Rodriguez-Alonso,et al. A Limulus anti-LPS factor-derived peptide modulates cytokine gene expression and promotes resolution of bacterial acute infection in mice[J]. International Immunopharmacology , 2003,3 :247–256.
19. 王思理,胡冠时,贡立青主编,细菌内毒素检查法及其应用. 北京,气象出版社出版,2003;1,214-218
20. 20、Altschul, Stephen F., Thomas L. Madden,et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs.Nucleic Acids Res. 1997, 25:3389-3402
21. Combet C, Blanchet C, Geourjon C, et al.NPS@: Network Protein Sequence Analysis TIBS ,2000 March Vol. 25, No 3 [291]:147-150
22. Rost, Burkhard; Sander, Chris: Combining evolutionary information and neural networks to predict protein secondary structure. Proteins, 1994, 19, 55-72.
23. 仇缀白主编,药物设计学(M). 北京,高等教育出版社出版. 2001,7:230-231
24. Goodford PJ,A .Computional procedure for determing energetically favorable binding sites on biologically important macromolecules.Med Chem,1985,28(7):849-857
25. Hendrickson MA,Nicklans MC,Milne GNA.CONCORD,etal .Comparison of computer-generated chemical structures with X ray crystallographic data.Chem Inf
comput sci,1993;33(1):155-163
26. Meng EC,Shoichet BK,Kuntz ID. Automated docking with grid-based energy evaluation.Comp Chem,1992;13(4):505-524
27. 骆兆文, 来鲁华综述, 基于蛋白质结构的药物分子设计.国外医学药学分册,1995;22(6):331-336
28. 赵金城, 王庆莉, 毕秀玲. 计算机辅助直接药物分子设计. 大连大学学报,2002,23(6):22-30
29. 林克江, 刘智华, 尤启冬.α、β多肽抗菌活性的定量构效关系研究. 药物生物技术,2003, 10(5): 299～302
30. Sternberg MJE. Protein structure prediction-a practical approach.Oxford:Oxford Pres
31. 赵国屏等编著.生物信息学. 北京, 科学出版社,2002.177-178
32. DG George, WC Barker and LT Hunt Mutation Data Matrix and Its Uses. Methods in Enzymology , 1990, 183; 341
33. Carl-Ivar Branden, John Tooze .Introduction to Protein Structure. Garland Publishing ,1991,210
34. 阎隆飞,孙之荣.蛋白质分子结构. 北京, 清华大学出版社,1999
35. 罗小民, 蒋华良, 沈建华等. 药物分子设计研究进展. 中国科学院院刊2003(4): 255-259
36. Guha M, Mackman N. LPS induction of gene expression in human monocytes. Cellular Signalling, 2001, 13: 85-94.
37. Wyckoff TJO, Raetz CRH, Jackman JE. Antibacterial and anti-inflammatory agents that target endotoxin. Trends in Microbiol. 1998, 6(4): 154-159。
38. Holst O, Ulmer AJ, Brade H, et al. Biochemistry and cell biology of bacterial endotoxin. FEMS Immunol. Med. Microbiol. 1996, 16: 83-104
39. Caroff M, Karibian D, Cavaillon J-M, et al.. Structural and functional analyses of bacterial lipopolysaccharides. Microbes and Infection, 2002, 4: 915-926.
40. 申吉泓,抗菌肽及其临床应用现状,昆明医学院学报. 2003,(4):26～28
41. 李孝东,袁建华. 抗菌肽的研究进展. 山东医药工业,2003,22(1):27-28
42. Rustici A, Velucchi M, Faggioni R, etal.Molecular mapping and detoxification of the lipid A binding site by synthetic peptides. Science. 1993 Jan 15;259(5093):361-5.
43. 生物信息学方法与实践,张成岗,贺福初编著. 北京, 科学出版社,2002.6.138-140
44. 陶慰孙,李惟,姜涌明等.蛋白质分子基础(第三版)[M].北京:高等教育出版社,1995.133～147
45. Altreuter DH,Dodick JS,Clark DS.Solid -phase peptide synthesis by ion-paired alpha chymotrypsin in nonaqueous media .Biotechnol Bioeng, ,2003,81(7):809 817
46. Gellerman G,Elgavi A,Salitra Y,etal.Facile synthesis of orthogonally protected amino acid building blocksfor combinatorial N-backbone cyclic peptide chemistry.Pept Res, 2001,57(4):277 –291
47. Boeijen A,van Ameijde J,liskimp RM.Solid phase synthesis of oligoure peptidomimetics employing the Fmoc protection strategy.Org Chem, 2001,66(25):8454 –8462
48. Redman JE,Ghadiri MR.Synthesis of photoactive p-azido tetrafluorophenylalaine containing peptide by solid phase Fmoc methodology.Org Lett,. 2002,4(25):4467-4469
49. Zhang Y,Kennan AJ.Efficient introduction of protected guanidiines in Boc solid phase peptide synthesis.Org Lett, 2001,3(15):2341-2344
50. de la Torre Beatriz G,Marcos Miguel A,Eritja Ramon,etal.Solid phase peptide synthesis using Nαtrityl amino acids.Lett Pept Sci,2001,8(6):331 –338
51. 韩香, 顾军, 苑庆兰, 甘一如. 人胸腺肽α1 的固相合成及体外活性研究. 中国药物化学杂志2004.02.15; 14(1): 27-29
52. Fields GB, Nobel RL. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int. J. peptide protein Res.1990,35: 161-214
53. Milton RC de L, Milton SCF, Adams PA. Prediction of difficult sequences in solid-phase peptide synthesis. J.Am.Chem.Soc., 1990, 112(16): 6039-6046
54. Narita M, Fukunaga T, Wakabayashi A, et al. Syntheses and properties of tertiary peptide bond-containing polypeptides. Int. J. Pept. Protein Res., 1984, 23: 306-314
55. Chan WC, White PD. Fmoc solid phase peptide synthesis. A practical approach. Oxford university press, 2000
56. Takashi Mizuma,Satoshi Masubushi,Shoji Augzu J.Pharm. Pharmacol. 1997, 49, 1067-1071;
57. Pauletti,G.M.,Okumu,F.W.,Borchardt,R.T., Effect of size and charge on the passive diffusion of peptides across Caco-2 cell monolayers via the paracellular pathway. Parm.
Res. 1997, 14(2): 164-8.
58. Gilon,C.,alle,D.,Chorev,M.,Selinger,Z.,Byk,G., Backbone cyclization: A new method for conferring conformational constraint on peptides. Biopolymers 1991,31,745-750
59. Siemion,Ignacy Z, Pol. Chem. 1989,63(4-12),431-438
60. Darshan Rangana,V.Haridas , Isabella L. J. Am. Chem. Soc. 1998,120(12),2695-272
61. Hocart S J,Simon J, etal. Potent antagonists of somatostatin: synthesis and biology. Med. Chem. 1998,41(7),1146-1154
62. D.S. Seetharaman Jois, Dananjay Pal,Scott a.Tibbetts,etal. Pept. Res. 1997,49, 517-526
63. Muriel Amblaard,Marc Rodriguez,Marie Francoise Lignon Eur. Med. Chem. 1998,33,171-180
64. Kevin Shreder, li Zhang, Trunghan Dang etal. Med. Chem. 1998,41,2631-2635
65. Jubilut GN,Cilli EM,Tominaga M,etal.Evaluation of thetrifluoromethanosule cleavage procedure for application in solid phase peptide synthesis.Chem Pharm Bull (Tokyo),2001,49(9):1089 –1092
66. de-Haas CJ, Haas PJ, van-Kessel KP, et al. Affinities of different proteins and peptides for lipopolysaccharide as determined by biosensor technology. Biochem-Biophys-Res-Commun, 1998, 252(2): 492-496
67. Fairlie,D.P.,Abbenante,G.,March,D.R., Curr. Med. Chem. 1995,2,654-686
68. Bruce J,Aungst and Hirosi Saitoh, Pharmaceutical Researc 1996,13(1):114-119
69. Dae-Yeon Suh,Yong Chul Kim,Young-Hwa Kang J.Nat. Prod. 1997,60,265-269
70. Bogdanowich-Knipp,S.J.,Jois D.S.S.,Siahaan T.J. The effect of conformation on the solution stability of linear vs. cyclic RGD peptides. Pept. Res. 1999,53,523-529
71. Maloy, W. L.,Kari, U. P. Structure-activity studies on magainins and other host defense peptides. Biopolymers. 1995,37, 105-112
72. Matsuzaki, K., Nakamura, A., Murase, O.,etal.. Membrane permeabilization mechanisms of a cyclic antimicrobial peptide,tachyplesin I and its linear analog. Biochemistry.1997, 36: 2104—2111
73. Lee, J.-Y., Boman, A., Chuanxin, S.,etal. Antibacterial peptides from pig intestine : isolation of a mammalian cecropin. Proc. Natl. Acad. Sci. 1989,86: 9159-9162
74. Zasloff, M., Martin, B. ,Chen, H. C, etal. Antimicrobial activity of synthetic magainin peptides and several analogues. Proc. Natl. Acad. Sci. 1988, 85:910-913
75. Matsuyama, K, Natori, S. Molecular cloning of cDNA for sapecin and unique expression of the sapecin gene during the development of Sarcophaga peregrina. J. Biol. Chem. 1988; 263, 17112-17116
76. Agerberth, B., Lee, J.-Y., Bergman, T., etal. Amino acid sequence of PR-39. Isolation from pig intestine of a new member of the family of proline-arginine-rich antibacterial peptides. Eur. J. Biochem. 1991,202:849-854
77. Orivel J,RedekerV,LE Caer JP,etal .Ponericins, new antibacterial and insecticidal peptides from the venom of the ant Pachycondyla goeldii.Biol Chem,2001,276(21):17823
78. Conlon JM,Kim JB.A protease inhibitor of the kunitz family from skin secretions of the tomato frog,dyscophs guinety(microhylidae). Biochem Biophys Res Commun, 2000, 279(3):961
79. Kevin H M, Judith H, Helen C,etal. Structure–function relationships in novel peptide dodecamers with broad-spectrum bactericidal and endotoxin-neutralizing activities. Biochem. 2000,349; 717-728)
80. Jorg Andra, Marta Lamatab, Guillermo Martinez de Tejada , etal.Biochemical Pharmacology 68 (2004) 1297–1307
81. Wright, S.D., Ramos, R.A., Patel, M., etal. Septin: a factor in plasma that opsonizes lipopolysaccharide-bearing particles for recognition by CD14 on phagocytes. Exp. Med. 1992,176: 719-727)
2. Darveau RP. Lipid A diversity and the innate host response to bacterial. Curr. Opin. Microbiol. 1998, 1: 36-42
3. Verhoef J, Hustinx WM, Frasa H, et al. Issues in the adjunct therapy of severe sepsis. J. Antimicrob. Chemother. 1996, 38(20): 167
4. Angus DC,Linde-Zwirble WT,Lidicker J, et al.Epidemiology of severe sepsis in the United States:analysis Of incidence,outcome,and associated costs of care. Crit. Care Med. 2001, 29(7): 1303-1310
5. rawford JH, Yang S, Zhou M,et al. Down-regulation of hepatic CYP1A2 plays an important role in inflammatory responses in sepsis. Crit Care Med. 2004;32(2):502-508
6. Hoshino K,Takeuchi O,Kawai T.et al.Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol. 1999; 162(7): 3749-3752
7. Waage A, Brandtzaeg P, Halstensen A, et al.. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome J. Exp. Med. 1989 169: 333-338
8. Vincent JL, Sun Q, Dubois MJ. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clini Infec Disea. 2002;34:1084-1093.
9. Ma J, Chen T, Mandelin J, et al. Regulation of macrophage activation. Cell Mol Life Sci. 2003;60(11):2334-2346.
10. Ried C, Wahl C, Miethke T, etal. High Affinity Endotoxin-binding and Neutralizing Peptides Based on the Crystal Structure of Recombinant Limulus Anti-lipopolysaccharide Factor. J. Biol. Chem, 1996 ,271(8):28120-28127
11. Kloczewiak M, Black KM, Loiselle P,et al.Synthetic peptides that mimic the binding site of hor seshoe crab antilipopolysaccharide factor.J Infect Dis,1994,170(6):1490-7
12. Roth RI, Su D, Child AH,et al.Limulus antilipopolysaccharide factor prevents mortality late in the course of endotoxemia. J Infect Dis, 1998 ,177(2):388-94
13. Warren HS, Glennon ML, Wainwright N, et al.Binding and neutralization of endotoxin by Limulus antilipopolysaccharide factor. Infect Immun ,1992 ,60(6):2506-13
14. Hoess A, Watson S, Siber G.R, et al.Crystal structure of an endotoxin-neutralizing protein from the horseshoe crab,Limulus anti-LPS factor, at 1.5? resolution. J EMBO,1993,12(9):3351-3356
15. Alpert G, Baldwin G, et al.Thompson C, Limulus antilipopolysaccharide factor protects rabbits from meningococcal endotoxin shock. J Infect Dis ,1992 ,165(3):494-500
16. Dong-Ning Wang, Jie-Wu Liu, Guan-Zhen Yang,et al.Cloning of Anti-LPS Factor cDNA from Tachypleus tridentatus,Expression in Bombyx mor/Larvae and Its Biological Activity In Vitro.Molecular biotechnology.2002,21:1-7
17. Maribel G. V, Luis A. G, Osvaldo R, et al. A Limulus Antilipopolysaccharide Factor-Derived Peptide Exhibits a New Immunological Activity with Potential Applicability in Infectious Diseases[J]. Clinical and Diagnostic Laboratory Immunology, 2000, 7(4):669-675.
18. Maribel G. V, J.C. Alvarez-Obregon, I. Rodriguez-Alonso,et al. A Limulus anti-LPS factor-derived peptide modulates cytokine gene expression and promotes resolution of bacterial acute infection in mice[J]. International Immunopharmacology , 2003,3 :247–256.
19. 王思理,胡冠时,贡立青主编,细菌内毒素检查法及其应用. 北京,气象出版社出版,2003;1,214-218
20. 20、Altschul, Stephen F., Thomas L. Madden,et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs.Nucleic Acids Res. 1997, 25:3389-3402
21. Combet C, Blanchet C, Geourjon C, et al.NPS@: Network Protein Sequence Analysis TIBS ,2000 March Vol. 25, No 3 [291]:147-150
22. Rost, Burkhard; Sander, Chris: Combining evolutionary information and neural networks to predict protein secondary structure. Proteins, 1994, 19, 55-72.
23. 仇缀白主编,药物设计学(M). 北京,高等教育出版社出版. 2001,7:230-231
24. Goodford PJ,A .Computional procedure for determing energetically favorable binding sites on biologically important macromolecules.Med Chem,1985,28(7):849-857
25. Hendrickson MA,Nicklans MC,Milne GNA.CONCORD,etal .Comparison of computer-generated chemical structures with X ray crystallographic data.Chem Inf
comput sci,1993;33(1):155-163
26. Meng EC,Shoichet BK,Kuntz ID. Automated docking with grid-based energy evaluation.Comp Chem,1992;13(4):505-524
27. 骆兆文, 来鲁华综述, 基于蛋白质结构的药物分子设计.国外医学药学分册,1995;22(6):331-336
28. 赵金城, 王庆莉, 毕秀玲. 计算机辅助直接药物分子设计. 大连大学学报,2002,23(6):22-30
29. 林克江, 刘智华, 尤启冬.α、β多肽抗菌活性的定量构效关系研究. 药物生物技术,2003, 10(5): 299～302
30. Sternberg MJE. Protein structure prediction-a practical approach.Oxford:Oxford Pres
31. 赵国屏等编著.生物信息学. 北京, 科学出版社,2002.177-178
32. DG George, WC Barker and LT Hunt Mutation Data Matrix and Its Uses. Methods in Enzymology , 1990, 183; 341
33. Carl-Ivar Branden, John Tooze .Introduction to Protein Structure. Garland Publishing ,1991,210
34. 阎隆飞,孙之荣.蛋白质分子结构. 北京, 清华大学出版社,1999
35. 罗小民, 蒋华良, 沈建华等. 药物分子设计研究进展. 中国科学院院刊2003(4): 255-259
36. Guha M, Mackman N. LPS induction of gene expression in human monocytes. Cellular Signalling, 2001, 13: 85-94.
37. Wyckoff TJO, Raetz CRH, Jackman JE. Antibacterial and anti-inflammatory agents that target endotoxin. Trends in Microbiol. 1998, 6(4): 154-159。
38. Holst O, Ulmer AJ, Brade H, et al. Biochemistry and cell biology of bacterial endotoxin. FEMS Immunol. Med. Microbiol. 1996, 16: 83-104
39. Caroff M, Karibian D, Cavaillon J-M, et al.. Structural and functional analyses of bacterial lipopolysaccharides. Microbes and Infection, 2002, 4: 915-926.
40. 申吉泓,抗菌肽及其临床应用现状,昆明医学院学报. 2003,(4):26～28
41. 李孝东,袁建华. 抗菌肽的研究进展. 山东医药工业,2003,22(1):27-28
42. Rustici A, Velucchi M, Faggioni R, etal.Molecular mapping and detoxification of the lipid A binding site by synthetic peptides. Science. 1993 Jan 15;259(5093):361-5.
43. 生物信息学方法与实践,张成岗,贺福初编著. 北京, 科学出版社,2002.6.138-140
44. 陶慰孙,李惟,姜涌明等.蛋白质分子基础(第三版)[M].北京:高等教育出版社,1995.133～147
45. Altreuter DH,Dodick JS,Clark DS.Solid -phase peptide synthesis by ion-paired alpha chymotrypsin in nonaqueous media .Biotechnol Bioeng, ,2003,81(7):809 817
46. Gellerman G,Elgavi A,Salitra Y,etal.Facile synthesis of orthogonally protected amino acid building blocksfor combinatorial N-backbone cyclic peptide chemistry.Pept Res, 2001,57(4):277 –291
47. Boeijen A,van Ameijde J,liskimp RM.Solid phase synthesis of oligoure peptidomimetics employing the Fmoc protection strategy.Org Chem, 2001,66(25):8454 –8462
48. Redman JE,Ghadiri MR.Synthesis of photoactive p-azido tetrafluorophenylalaine containing peptide by solid phase Fmoc methodology.Org Lett,. 2002,4(25):4467-4469
49. Zhang Y,Kennan AJ.Efficient introduction of protected guanidiines in Boc solid phase peptide synthesis.Org Lett, 2001,3(15):2341-2344
50. de la Torre Beatriz G,Marcos Miguel A,Eritja Ramon,etal.Solid phase peptide synthesis using Nαtrityl amino acids.Lett Pept Sci,2001,8(6):331 –338
51. 韩香, 顾军, 苑庆兰, 甘一如. 人胸腺肽α1 的固相合成及体外活性研究. 中国药物化学杂志2004.02.15; 14(1): 27-29
52. Fields GB, Nobel RL. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int. J. peptide protein Res.1990,35: 161-214
53. Milton RC de L, Milton SCF, Adams PA. Prediction of difficult sequences in solid-phase peptide synthesis. J.Am.Chem.Soc., 1990, 112(16): 6039-6046
54. Narita M, Fukunaga T, Wakabayashi A, et al. Syntheses and properties of tertiary peptide bond-containing polypeptides. Int. J. Pept. Protein Res., 1984, 23: 306-314
55. Chan WC, White PD. Fmoc solid phase peptide synthesis. A practical approach. Oxford university press, 2000
56. Takashi Mizuma,Satoshi Masubushi,Shoji Augzu J.Pharm. Pharmacol. 1997, 49, 1067-1071;
57. Pauletti,G.M.,Okumu,F.W.,Borchardt,R.T., Effect of size and charge on the passive diffusion of peptides across Caco-2 cell monolayers via the paracellular pathway. Parm.
Res. 1997, 14(2): 164-8.
58. Gilon,C.,alle,D.,Chorev,M.,Selinger,Z.,Byk,G., Backbone cyclization: A new method for conferring conformational constraint on peptides. Biopolymers 1991,31,745-750
59. Siemion,Ignacy Z, Pol. Chem. 1989,63(4-12),431-438
60. Darshan Rangana,V.Haridas , Isabella L. J. Am. Chem. Soc. 1998,120(12),2695-272
61. Hocart S J,Simon J, etal. Potent antagonists of somatostatin: synthesis and biology. Med. Chem. 1998,41(7),1146-1154
62. D.S. Seetharaman Jois, Dananjay Pal,Scott a.Tibbetts,etal. Pept. Res. 1997,49, 517-526
63. Muriel Amblaard,Marc Rodriguez,Marie Francoise Lignon Eur. Med. Chem. 1998,33,171-180
64. Kevin Shreder, li Zhang, Trunghan Dang etal. Med. Chem. 1998,41,2631-2635
65. Jubilut GN,Cilli EM,Tominaga M,etal.Evaluation of thetrifluoromethanosule cleavage procedure for application in solid phase peptide synthesis.Chem Pharm Bull (Tokyo),2001,49(9):1089 –1092
66. de-Haas CJ, Haas PJ, van-Kessel KP, et al. Affinities of different proteins and peptides for lipopolysaccharide as determined by biosensor technology. Biochem-Biophys-Res-Commun, 1998, 252(2): 492-496
67. Fairlie,D.P.,Abbenante,G.,March,D.R., Curr. Med. Chem. 1995,2,654-686
68. Bruce J,Aungst and Hirosi Saitoh, Pharmaceutical Researc 1996,13(1):114-119
69. Dae-Yeon Suh,Yong Chul Kim,Young-Hwa Kang J.Nat. Prod. 1997,60,265-269
70. Bogdanowich-Knipp,S.J.,Jois D.S.S.,Siahaan T.J. The effect of conformation on the solution stability of linear vs. cyclic RGD peptides. Pept. Res. 1999,53,523-529
71. Maloy, W. L.,Kari, U. P. Structure-activity studies on magainins and other host defense peptides. Biopolymers. 1995,37, 105-112
72. Matsuzaki, K., Nakamura, A., Murase, O.,etal.. Membrane permeabilization mechanisms of a cyclic antimicrobial peptide,tachyplesin I and its linear analog. Biochemistry.1997, 36: 2104—2111
73. Lee, J.-Y., Boman, A., Chuanxin, S.,etal. Antibacterial peptides from pig intestine : isolation of a mammalian cecropin. Proc. Natl. Acad. Sci. 1989,86: 9159-9162
74. Zasloff, M., Martin, B. ,Chen, H. C, etal. Antimicrobial activity of synthetic magainin peptides and several analogues. Proc. Natl. Acad. Sci. 1988, 85:910-913
75. Matsuyama, K, Natori, S. Molecular cloning of cDNA for sapecin and unique expression of the sapecin gene during the development of Sarcophaga peregrina. J. Biol. Chem. 1988; 263, 17112-17116
76. Agerberth, B., Lee, J.-Y., Bergman, T., etal. Amino acid sequence of PR-39. Isolation from pig intestine of a new member of the family of proline-arginine-rich antibacterial peptides. Eur. J. Biochem. 1991,202:849-854
77. Orivel J,RedekerV,LE Caer JP,etal .Ponericins, new antibacterial and insecticidal peptides from the venom of the ant Pachycondyla goeldii.Biol Chem,2001,276(21):17823
78. Conlon JM,Kim JB.A protease inhibitor of the kunitz family from skin secretions of the tomato frog,dyscophs guinety(microhylidae). Biochem Biophys Res Commun, 2000, 279(3):961
79. Kevin H M, Judith H, Helen C,etal. Structure–function relationships in novel peptide dodecamers with broad-spectrum bactericidal and endotoxin-neutralizing activities. Biochem. 2000,349; 717-728)
80. Jorg Andra, Marta Lamatab, Guillermo Martinez de Tejada , etal.Biochemical Pharmacology 68 (2004) 1297–1307
81. Wright, S.D., Ramos, R.A., Patel, M., etal. Septin: a factor in plasma that opsonizes lipopolysaccharide-bearing particles for recognition by CD14 on phagocytes. Exp. Med. 1992,176: 719-727)